Amarin (AMRN) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $197M

Market Cap: $311.2MFounded: 1989HQ: Dublin, Ireland

Sector Ranking#233 in Small Molecule Drugs

Overview

Amarin is a commercial-stage biopharmaceutical company focused on redefining cardiovascular disease (CVD) management. Its success is built upon the landmark REDUCE-IT outcomes trial for its flagship product, icosapent ethyl (VASCEPA/VAZKEPA), which demonstrated significant cardiovascular risk reduction in high-risk patients on statins. The company's strategy centers on maximizing the global commercial footprint of this proven therapy while exploring additional pipeline opportunities to expand its impact on cardiometabolic health.

Cardiovascular DiseaseCardiometabolic Health

Technology Platform

Amarin's platform is centered on the deep pharmaceutical development, clinical validation, and commercialization of highly purified icosapent ethyl, supported by expertise in executing large-scale cardiovascular outcomes trials.

Funding History

4

Total raised:$197M

PIPE$100MUndisclosedDec 15, 2019

IPO$62MUndisclosedJun 30, 2005

Series B$25MUndisclosedJun 15, 2001

Series A$10MUndisclosedJun 15, 1999

Opportunities

The primary opportunity lies in capturing a significant share of the tens of millions of high-risk cardiovascular patients globally who have residual risk despite statin therapy, driven by guideline recommendations and international expansion.

Successfully developing or in-licensing additional cardiometabolic assets would leverage its commercial infrastructure for future growth.

Risk Factors

Extreme product concentration on icosapent ethyl exposes the company to generic competition, reimbursement pressures, and competitive displacement by newer drug classes.

Achieving profitability and funding growth while navigating international expansion and a thin pipeline presents significant execution and financial risk.

Competitive Landscape

Icosapent ethyl occupies a unique niche with robust outcomes data, but faces indirect competition from cardioprotective GLP-1s and SGLT2 inhibitors, as well as long-term generic threats. Its competitive moat is the strength of the REDUCE-IT trial evidence, but maintaining market share requires effective commercialization against evolving standards of care.